Treatment of Angiotensin Peptide (1-7) for COVID-19

Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04375124

Enrollment

Registered

2020-05-05

Start date

2020-04-25

Completion date

2020-09-30

Last updated

2022-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

Detailed description

Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of plasma derived angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

Interventions

BIOLOGICALBiological/Vaccine: Angiotensin peptide (1-7) derived plasma

angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

This group will receive angiotensin peptide (1-7) during their treatment at hospital.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* accepted to participate with an informed consent * proven positive COVID-19

Exclusion criteria

* declined to participate * genetic/chromosomal abnormalities * any kind of history of previous adverse events with transfusion * diagnosis of immune deficiency

Design outcomes

Primary

Measure	Time frame	Description
mortality	4 months	mortality rates in two groups will be compared

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026